Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND).

Adam S. Kibel,Charles G. Drake,Evan Y. Yu,Nicholas J. Vogelzang,John M. Corman,Lawrence Karsh,Aymen Elfiky,Neal D. Shore,Frederick Millard,Nancy N. Chang,Emmanuel S. Antonarakis

Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND).

2017

Adam S. Kibel
Charles G. Drake
Evan Y. Yu
Nicholas J. Vogelzang
John M. Corman
Lawrence Karsh
Aymen Elfiky
Neal D. Shore
Frederick Millard
Nancy N. Chang
Emmanuel S. Antonarakis

e16516Background: Identifying occult metastases in men with BRPC is critical, as treatment depends on disease state (biochemical recurrence vs oligometastatic disease). It is prudent to investigate...

Keywords:

Recurrent prostate cancer
Sipuleucel-T
Androgen deprivation therapy
Oncology
Occult
Pathology
Internal medicine
Medicine
in patient
oligometastatic disease
Biochemical recurrence
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations